| Literature DB >> 26378591 |
Huawei Zeng1, Dmitry Grapov2, Matthew I Jackson3, Johannes Fahrmann4, Oliver Fiehn5, Gerald F Combs6.
Abstract
The pattern of metabolites produced by the gut microbiome comprises a phenotype indicative of the means by which that microbiome affects the gut. We characterized that phenotype in mice by conducting metabolomic analyses of the colonic-cecal contents, comparing that to the metabolite patterns of feces in order to determine the suitability of fecal specimens as proxies for assessing the metabolic impact of the gut microbiome. We detected a total of 270 low molecular weight metabolites in colonic-cecal contents and feces by gas chromatograph, time-of-flight mass spectrometry (GC-TOF) and ultra-high performance liquid chromatography, quadrapole time-of-flight mass spectrometry (UPLC-Q-TOF). Of that number, 251 (93%) were present in both types of specimen, representing almost all known biochemical pathways related to the amino acid, carbohydrate, energy, lipid, membrane transport, nucleotide, genetic information processing, and cancer-related metabolism. A total of 115 metabolites differed significantly in relative abundance between both colonic-cecal contents and feces. These data comprise the first characterization of relationships among metabolites present in the colonic-cecal contents and feces in a healthy mouse model, and shows that feces can be a useful proxy for assessing the pattern of metabolites to which the colonic mucosum is exposed.Entities:
Keywords: cecal contents; colon; feces; mass spectrometry; metabolite
Year: 2015 PMID: 26378591 PMCID: PMC4588808 DOI: 10.3390/metabo5030489
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Figure 1Overview of significant differences in metabolite profiles between colonic mucosal, colonic-cecal content and feces sample type comparisons.
Unique metabolites and their respective biochemical pathways in colonic-cecal contents and feces.
| Colon-cecal contents | Feces |
|---|---|
| Unique metabolites | |
| 1-Hexadecanoyl-2-octadecadienoyl-sn-glycero-3-phosphocholine | 1H-Indole-3-carboxylic acid |
| L-Alanyl-L-norleucine | 1-Myristoyl-sn-glycero-3-phosphocholine |
| Leu-Val | 1-Octadecanoyl-sn-glycero-3-phosphocholine |
| N-Palmitoylsphingosine | Betaine |
| Palmityl-L-carnitine | L-Carnitine |
| Pregnan-20-one, 17-(acetyloxy)-3-hydroxy-6-methyl-, (3b,5b,6a)-(A) | Nicotinamide adenine dinucleotide (NAD) |
| 3a,12b-Dihydroxy-5b-cholanoic acid-(A) | Oxyquinoline |
| Deoxythymidine monophosphate (dTMP) | Pregnan-20-one, 17-(acetyloxy)-3-hydroxy-6-methyl-, (3b,5b,6a)-(B) |
| 13-hydroxy-9Z,11E-octadecadienoic acid | |
| 3a,12b-Dihydroxy-5b-cholanoic acid-(B) | |
| UDP-N-acetyl-D-galactosamine | |
| Respective biochemical pathways | |
| Ether lipid metabolism | Primary bile acid biosynthesis |
| Glycerophospholipid metabolism | Tryptophan metabolism |
| Metabolic pathways | Biosynthesis of secondary metabolites |
| Choline metabolism in cancer | Ether lipid metabolism |
| Valine, leucine and isoleucine degradation / biosynthesis | Glycerophospholipid metabolism |
| Sphingolipid metabolism | Metabolic pathways |
| Bile secretion | Choline metabolism in cancer |
| Fatty acid degradation | Glycine, serine and threonine metabolism |
| Steroid hormone biosynthesis | ABC transporters |
| Secondary bile acid biosynthesis | Bile secretion |
| Pyrimidine metabolism | Fatty acid degradation |
| Folate biosynthesis | |
| Nicotinate and nicotinamide metabolism | |
| Quinolines | |
| Phenylalanine, tyrosine and tryptophan biosynthesis | |
| Steroid hormone biosynthesis | |
| Biosynthesis of unsaturated fatty acids | |
| Linoleic acid metabolism | |
| Secondary bile acid biosynthesis | |
| Mucin type O-Glycan biosynthesis | |
| Amino sugar and nucleotide sugar metabolism | |
| Mucin type O-Glycan biosynthesis | |
Figure 2The heatmap displays relative increase/decrease of metabolite contents and their similarities between individual samples. In these visualization columns represent samples and rows variables, and hierarchical cluster analysis (HCA) was used to group samples and metabolites based on similarities in auto-scaled values and correlations, respectively. Cluster identities represent differing experimental biological or analytical variability; colors (red, relative increase; blue, relative decrease).
Figure 3Orthogonal signal correction partial least squares discriminant analysis (O-PLS-DA) was used to generate a multivariate classification model showing the relationship of the variance (in metabolites) and sample types (colonic-cecal content and feces). X and Y axis are O-PLS-DA sample scores for the first two latent variables. Color codes: pink, colonic-cecal contents; blue, feces.
Figure 4Biochemical and chemical similarity network highlighting important differences in metabolites abundance between colonic-cecal content and feces. Vertex size encodes the fold change in metabolite abundance between groups (when the metabolite abundance in colonic-cecal content was higher than that in feces, we defined it as “increase”; in contrast, if the metabolite abundance in colonic-cecal content was lower than that in feces, we defined it as “decrease”). Vertex shape (triangle, increase; “V”, decrease; ellipse, no change) and color (blue, decrease; red, increase; gray, insignificant change or p > 0.05 after-adjustment for FDR) are used to encode the significance and relative direction of changes in metabolites between colonic-cecal content and feces comparison.